{"disease":{"id":"astrocytoma-idh-mutant","name":"astrocytoma idh mutant"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05303519","title":"SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":365,"lead_sponsor_name":"Nuvation Bio Inc.","has_results":false},{"nct_id":"NCT05190172","title":"PRO-GLIO: PROton Versus Photon Therapy in IDH-mutated Diffuse Grade II and III GLIOmas","phase":"NA","overall_status":"RECRUITING","enrollment_count":225,"lead_sponsor_name":"Oslo University Hospital","has_results":false},{"nct_id":"NCT06047379","title":"Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":134,"lead_sponsor_name":"Neonc Technologies, Inc.","has_results":false},{"nct_id":"NCT03434262","title":"SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":68,"lead_sponsor_name":"St. Jude Children's Research Hospital","has_results":false},{"nct_id":"NCT05879367","title":"Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":66,"lead_sponsor_name":"Orbus Therapeutics, Inc.","has_results":false},{"nct_id":"NCT05375318","title":"BIOhabitats: Biological Validation of Vascular Habitats Within Astrocytoma Grade 4 at Molecular, Cellular, and Histopathological Levels","phase":"","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"Juan M Garcia-Gomez","has_results":false},{"nct_id":"NCT03528642","title":"Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":40,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04145115","title":"A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":37,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07301268","title":"GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT07468136","title":"Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":33,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT06625047","title":"Comparing Telehealth and In-person Assessments in Glioma Patients Receiving Oral Chemotherapy","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT06860594","title":"Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma","phase":"PHASE1","overall_status":"SUSPENDED","enrollment_count":30,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06815029","title":"Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":27,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT05789394","title":"Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma or Recurrent Astrocytoma in Patients Undergoing Craniotomy","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Mayo Clinic","has_results":false}],"total":14},"guidelines":[],"source":"Drug Landscape verified database"}